Literature DB >> 16106008

Quantifying the federal minimal risk standard: implications for pediatric research without a prospect of direct benefit.

David Wendler1, Leah Belsky, Kimberly M Thompson, Ezekiel J Emanuel.   

Abstract

United States federal regulations allow institutional review boards (IRBs) to approve pediatric research that does not offer participants a "prospect of direct" benefit only when the risks are minimal or a "minor" increase over minimal. The federal regulations define minimal risks based on the risks "ordinarily encountered in daily life or during routine physical or psychological examinations or tests." In the absence of empirical data, IRB members may assume they are familiar with the risks of daily life and with the risks of routine examinations and tests and rely on their own intuitive judgment to make these assessments. Yet intuitive judgment of risk is subject to systematic errors, highlighting the need for empirical data to guide IRB review and approval of pediatric research. Current data reveal that car trips pose the highest risk of mortality ordinarily encountered by healthy children. On average, these risks are approximately 0.06 per million for children aged 14 years and younger, and approximately 0.4 per million for children aged 15 through 19 years. Riskier, but still ordinary, car trips pose an approximately 0.6 per million chance of death for children aged 14 years and younger and an approximately 4 per million chance of death for children aged 15 through 19 years. Participation in sports represents the upper end of the range of morbidity risks for healthy children. For every million instances of playing basketball, approximately 1900 individuals will sustain injuries, including 180 broken bones and 58 permanent disabilities. These findings suggest IRBs are implementing the federal minimal risk standard too cautiously in many cases. These data also raise the question of whether the federal minimal risk standard may sometimes fail to provide sufficient protection for children, prompting the need to consider alternative standards.

Entities:  

Keywords:  Biomedical and Behavioral Research; Empirical Approach; Legal Approach

Mesh:

Year:  2005        PMID: 16106008     DOI: 10.1001/jama.294.7.826

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  40 in total

1.  Risks of propofol sedation/anesthesia for imaging studies in pediatric research: eight years of experience in a clinical research center.

Authors:  Ruwan Kiringoda; Audrey E Thurm; Matthew E Hirschtritt; Deloris Koziol; Robert Wesley; Susan E Swedo; Naomi P O'Grady; Zenaide M N Quezado
Journal:  Arch Pediatr Adolesc Med       Date:  2010-06

Review 2.  A framework for research ethics review during public emergencies.

Authors:  Catherine M Tansey; Margaret S Herridge; Ronald J Heslegrave; James V Lavery
Journal:  CMAJ       Date:  2010-06-07       Impact factor: 8.262

3.  Considerations in the evaluation and determination of minimal risk in pragmatic clinical trials.

Authors:  John D Lantos; David Wendler; Edward Septimus; Sarita Wahba; Rosemary Madigan; Geraldine Bliss
Journal:  Clin Trials       Date:  2015-09-15       Impact factor: 2.486

4.  Ethical issues in clinical trials involving nanomedicine.

Authors:  David B Resnik; Sally S Tinkle
Journal:  Contemp Clin Trials       Date:  2006-11-17       Impact factor: 2.226

5.  A standard for assessing the risks of pediatric research: pro and con.

Authors:  David Wendler; Leonard Glantz
Journal:  J Pediatr       Date:  2007-06       Impact factor: 4.406

6.  Research involving wards of the state: protecting particularly vulnerable children.

Authors:  Sumeeta Varma; David Wendler
Journal:  J Pediatr       Date:  2008-01       Impact factor: 4.406

7.  Ethical assessment of pediatric research protocols.

Authors:  Robert D Truog
Journal:  Intensive Care Med       Date:  2007-11-03       Impact factor: 17.440

Review 8.  Accepting risk in clinical research: is the gene therapy field becoming too risk-averse?

Authors:  Claire T Deakin; Ian E Alexander; Ian Kerridge
Journal:  Mol Ther       Date:  2009-09-22       Impact factor: 11.454

9.  Minimal or reasonable? Considering the ethical threshold for research risks to nonconsenting bystanders and implications for nonconsenting participants.

Authors:  Holly Fernandez Lynch
Journal:  Bioethics       Date:  2020-02-24       Impact factor: 1.898

10.  No child left behind: Enrolling children and adults simultaneously in critical care randomized trials.

Authors:  Scott D Halpern; Adrienne G Randolph; Derek C Angus
Journal:  Crit Care Med       Date:  2009-09       Impact factor: 7.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.